Study S000317

Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients: Study Protocol of a Randomized, Parallel -Controlled Clinical Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06924697
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: SINGLE
Status: ENROLLING_BY_INVITATION
Enrollment: 46
Start: 2025-06-21
Primary completion: 2026-01-11
Lead sponsor: Shanghai East Hospital
Conditions: Diabetes Mellitus, Type 2; Nicotine Dependence, Cigarettes
Interventions: DRUG:Application of GLP-1RAs drugs; DRUG:DPP-4i group
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Fagerstrom Test of Nicotine Dependence (FTND) scores [From enrollment to the end of treatment at 24 weeks.At weeks 0 and 24]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001132	Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial. Chen D, Frontiers in clinical diabetes and healthcare	2026	Protocol	PMID 41704542 DOI	cites ClinicalTrials.gov:NCT06924697; registry reference DERIVED:41704542